|
|
|
|
Alcon Discontinues Trials For Anecortave Acetate
Amount of IOP reduction and responder rate provided by the highest dose, were not sufficient to support the approach Related News Patient to be randomised to receive once-daily dose of placebo, tiotropium bromide or 50g of NVA237 ...
|
|
|
Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure Reduction
- The Phase 2 study was rigorously designed to evaluate the safety and three-month IOP-lowering efficacy of a single anterior juxtascleral injection of three doses of anecortave acetate (24mg, 48mg and 60mg) versus vehicle.The mean...
|
|
|
Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure Reduction
- Alcon, Inc.(NYSE:ACL) announced today that it has discontinued development of anecortave acetate for the reduction of intraocular pressure (IOP) associated with glaucoma. The company recently reviewed interim efficacy and safety data...
|
|
|
Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure Reduction
Alcon, Inc.(NYSE:ACL) announced today that it has discontinued development of anecortave acetate for the reduction of intraocular pressure (IOP) associated with glaucoma. The company recently reviewed interim efficacy and safety data...
|
|
|
Zebinix Anti-Epileptic Shows Long-Term Success
Research conducted at Yale University School of Medicine has shown that Zebinix, a once-daily anti-epileptic drug, can help to decrease seizure frequency over the long term.Results from a one-year extension of an Eslicarbazepine ...
|
|
|
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
MAMEDE DO CORONADO, Portugal, June 29/PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and...
|
|
|
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Data presented yesterday, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix* (eslicarbazepine acetate; ESL) resulted in a marked and sustained decrease in seizure frequency over the long-term....
|
|
|
Zebinix Shows Long-Term Reduction In Seizure Frequency
Zebinix, once-daily anti-epileptic that helps to decrease seizure frequency over the long-term Results from the one-year extension of a pivotal Eslicarbazepine Acetate phase III study showed that add-on treatment with once-daily anti...
|
|
|
Bial Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R
MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and...
|
|
|
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and...
|
|
|
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and...
|
|
|
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
MAMEDE DO CORONADO, ) S.MAMEDE DO CORONADO, Portugal, June 29, 2009 /PRNewswire via COMTEX/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine...
|
|
|
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and...
|
|
|
The Effects of Rosiglitazone, Metformin, and Estradiol-Cyproterone Acetate on Lean Patients With Polycystic Ov
Save in My Library Free Abstract Cetinkalp S et al.- The data show that in women with PCOS, ECA is more effective than insulin-sensitizing drugs such as rosiglitazone and metformin in improving menstrual pattern and reducing serum free...
|
|
|
Sepracor's STEDESA (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA
Save in My Library Free Abstract Sepracor Inc.announced that it has been notified by the U.S. Food and Drug Administration that the New Drug Application for STEDESA has been accepted for filing and is now under formal review. As...
|
|
|
Medical News: Sepracor's STEDESA (Eslicarbazepine Acetate) New Drug Application Formally Accepted For Review
Main Category: Epilepsy Also Included In: Regulatory Affairs / Drug Approvals email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: Health Professional: Article Opinions: Sepracor...
|
|
|
Sepracor's STEDESA' (Eslicarbazepine Acetate) New Drug Application Formally Accepted For Review By The FDA
Sepracor Inc.(Nasdaq: SEPR) today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for STEDESA" (eslicarbazepine acetate) has been accepted for filing and is now...
|
|
|
Sepracor's STEDESA (Eslicarbazepine Acetate) New Drug Application Formally Accepted For Review By The FDA
Sepracor Inc.(Nasdaq: SEPR) today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for STEDESA (eslicarbazepine acetate) has been accepted for filing and is now under...
|
|
|
Sepracors STEDESA (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the
Sepracor Inc.(Nasdaq: SEPR) today announced that it has been notified by the U.S.Food and Drug Administration (FDA) that the New Drug Application (NDA) for STEDESA (eslicarbazepine acetate) has been accepted for filing and is now under...
|
|
|
Medical News: Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data At ASCO Annual
Cancer / Oncology News Main Category: Cancer / Oncology Also Included In: Clinical Trials / Drug Trials email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: Health Professional:...
|
|
|
Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data At ASCO Annual Meeting
Cougar Biotechnology, Inc.(NASDAQ:CGRB) announced that results from ongoing Phase II clinical trials of Cougar's investigational drug CB7630 (abiraterone acetate) were presented at the 2009 ASCO Annual Meeting that is currently taking...
|
|
|
Sepracor's STEDESA (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA
-- Submission includes data from three Phase III studies in more than 1,000 patients from 23 countries -- More than 3 million people in the U.S.Sepracor's STEDESA (Eslicarbazepine Acetate) New Drug Application Formally Accepted for...
|
|
|
SepracorEURs STEDESA„ (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by
-- More than 3 million people in the U.S.are afflicted with epilepsy and seizures1 -- U.S. epilepsy treatment market estimated to be $3.5 billion2 MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that...
|
|
|
Sepracors STEDESA (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA
- Sepracor Inc.(Nasdaq: SEPR) today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for STEDESA (eslicarbazepine acetate) has been accepted for filing and is now...
|
|
|
Sepracors STEDESA (Eslicarbazepine Acetate) New Drug Application Formal
Sepracor Inc.(Nasdaq: SEPR) today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for STEDESA (eslicarbazepine acetate) has been accepted for filing and is now under...
|
